Rukobia Archives -

Gilead Sciences has claimed FDA approval for Sunlenca, a therapy from Gilead Sciences for people with multidrug-resistant (MDR)

FDA approves twice-yearly resistant HIV therapy from Gilead

https://pharmaphorum.com/news/fda-approves-twice-yearly-resistant-hiv-therapy-from-gilead/

The European Commission has become the first regulator worldwide to approved a therapy from Gilead Sciences for people

Gilead bags first approval for twice-yearly HIV therapy

https://pharmaphorum.com/news/gilead-bags-first-approval-for-twice-yearly-hiv-therapy/

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to

Gilead tries again with twice-yearly HIV drug lenacapavir

https://pharmaphorum.com/news/gilead-tries-again-with-twice-yearly-hiv-drug-lenacapavir/

Gilead Sciences has filed for FDA approval of a long-acting therapy for resistant HIV infections that only needs

Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy

https://pharmaphorum.com/news/gilead-challenges-viiv-in-resistant-hiv-filing-twice-yearly-therapy/

Rukobia